EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing significant challenges, primarily due to a patent cliff and a lack of earnings momentum following the COVID-19 pandemic. Many experts express concerns over its drug pipeline, indicating that the company is in need of a blockbuster drug to drive future growth. While it maintains an attractive dividend yield—ranging from 6.4% to 7%—there is skepticism about the sustainability of this yield if new profitable drugs are not developed soon. The stock’s valuation is seen as low, trading at around 8-10 times earnings, which some experts believe might make it appealing for patient investors. However, the consensus also points to caution due to the industry-wide challenges, including cost-cutting measures and potential government pressure on drug pricing.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
TOP PICK

Pfizer Inc(PFE)

Feb 28, 2011
New CEO is changing the company compared to the other pharmas. R&D has been a big pit for all companies and he is cutting this back. Will be basically be cutting the company into smaller parts.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$19.24

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 11, 2011
Not keen on the big pharma complex at this stage. This one in particular has had struggles with their pipeline. There are better ways to play the health care space.
Photo of Karl BergerKarl BergerUnlock Rating
$18.83

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 05, 2011
(A Top Pick Feb 3/10. Down 0.29%.) Model price is $29.91, an upside of 62%. Good dividend. His earnings estimate shows $2.22. Still a Buy.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$18.11

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 23, 2010
A lot of the pharmaceuticals have been in the doldrums for a long time. Large dividend yield and cheap on a PE basis but their large blockbuster drugs are coming off patent.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$17.61

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Dec 22, 2010
Coming out of the recession pharmaceuticals have not recovered to 2007 levels. Market worries about Obamacare and generics impact on branded drugs. Also worried about FDA approval process.. Also subject to litigation. Tremendous amount of cash and trading at very low multiples. Looking at this.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$17.56

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 17, 2010
Have had a lot of issues and the CEO has left. Has been an abysmal investment over the last 5-10 years. Decent dividend. What do they do when Lipitor goes off patent mid 2011? Their acquisition of Wyeth gives them a decent stream of products. Trading at 8X earnings. Everybody hates it so maybe it’s worth looking at.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$17.03

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 16, 2010
Looked at it a couple of times. Lots of cash, good name, but he has never been able to pull the trigger. He thinks you need to let it go up a bit and increase volume, but if you own it, you get paid to wait.
Photo of Rick StuchberryRick StuchberryUnlock Rating
$17.22

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 19, 2010
Concerned with risk from generic competition to the big pharmas. Prefers Teva (TEVA-Q). The big pharmas will continue to struggle because of this.
Photo of Karl BergerKarl Berger
No
Unlock Rating
$16.80

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 10, 2010
Lost its ability to grow because of its size. Lipitor represents 20% and it goes off patent next year so they’ll be competing with generics.
Photo of Gordon ReidGordon ReidUnlock Rating
$16.83

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 09, 2010
(Top Pick Nov 16/09, Down 5%) Drug stocks have been out of favour. Drug stocks bottomed earlier this year. Have a number of drugs coming off patent. Dividend investors have identified drug companies as targets.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$16.83

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 08, 2010
(Top Pick Nov 30/09, Down 4.77%) $28.23 model price. 64% upside. He keeps on buying it. Held for 4 years in his fund. There is value there and major consolidation going on there. It’s a changing landscape – they are getting together with generics.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.05

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 20, 2010
The whole pharma business is somewhat challenged. They spend lots developing a drug and then a few years later it goes Generic. One drug is a quarter of their business but it goes Generic in 2011. There are better places to go. This is more of a defensive stock. Would prefer a hybrid that just has pharma as a part of the their business.
Photo of Gordon ReidGordon ReidUnlock Rating
$17.66

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 05, 2010
(A Top Pick Oct 8/09. Up 5.36%.) Still likes.
Photo of Colin StewartColin Stewart
Owned
Unlock Rating
$17.23

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Sep 07, 2010
Has been a long-term sufferer. Product outlook is much better since the merger. They have started to increase their dividend again. This is a dividend stock with some upside potential.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$16.33

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 25, 2010
(Market Call Minute) Doesn’t buy US stocks.
Photo of Barry SchwartzBarry SchwartzUnlock Rating
$15.06

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 436 to 450 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica